Cost‐effectiveness of testosterone treatment utilising individual patient data from randomised controlled trials in men with low testosterone levels
Andrology · 2024
DOI: 10.1111/andr.13597 ↗At a glance
Journal article in Andrology, 2024. Written by Rodolfo Hernández and 9 co-authors. Institution: Health Economics Research Unit, University of Aberdeen, Foresterhill, Aberdeen, UK. Major MEDLINE topics: Testosterone, Cost-Benefit Analysis, Hypogonadism, Randomized Controlled Trials as Topic. 47 references. The full text is freely available (open access, CC BY 4.0). Funded by: Health Technology Assessment programme, Medical Research Council, National Institute for Health and Care Research.
Abstract (original language)
Background
Testosterone is safe and highly effective in men with organic hypogonadism, but worldwide testosterone prescribing has recently shifted towards middle‐aged and older men, mostly with low testosterone related to age, diabetes and obesity, for whom there is less established evidence of clinical safety and benefit. The value of testosterone treatment in middle‐aged and older men with low testosterone is yet to be determined. We therefore evaluated the cost‐effectiveness of testosterone treatment in such men with low testosterone compared with no treatment.
Methods
A cost‐utility analysis comparing testosterone with no treatment was conducted following best practices in decision modelling. A cohort Markov model incorporating relevant care pathways for individuals with hypogonadism was developed for a 10‐year‐time horizon. Clinical outcomes were obtained from an individual patient meta‐analysis of placebo‐controlled, double‐blind randomised studies. Three starting age categories were defined: 40, 60 and 75 years. Cost utility (quality‐adjusted life years) accrued and costs of testosterone treatment, monitoring and cardiovascular complications were compared to estimate incremental cost‐effectiveness ratios and cost‐effectiveness acceptability curves for selected scenarios.
Results
Ten‐year excess treatment costs for testosterone compared with non‐treatment ranged between £2306 and £3269 per patient. Quality‐adjusted life years results depended on the instruments used to measure health utilities. Using Beck depression index‐derived quality‐adjusted life years data, testosterone was cost‐effective (incremental cost‐effectiveness ratio
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Health Economics Research Unit, University of Aberdeen, Foresterhill, Aberdeen, UK.
- Faculty of Medicine, General Sir John Kotelawala Defence University, Colombo, Sri Lanka.
- Department of Metabolism, Digestion and Reproduction, Imperial College, London, UK.
- Health Service Research Unit, University of Aberdeen, Aberdeen, UK.
- Translational & Clinical Research Institute, University of Newcastle upon Tyne, Newcastle Upon Tyne, UK.
- Department of Endocrinology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
ORCID profiles: Channa N Jayasena
Funding
- Health Technology Assessment programme
- Medical Research Council
- National Institute for Health and Care Research
Cite
APA
Hernández, R., de Silva, N. L., Hudson, J., Cruickshank, M., Quinton, R., Manson, P., Dhillo, W. S., Bhattacharya, S., Brazzelli, M., & Jayasena, C. N. (2024). Cost‐effectiveness of testosterone treatment utilising individual patient data from randomised controlled trials in men with low testosterone levels. Andrology. https://doi.org/10.1111/andr.13597
Vancouver
Hernández R, de Silva NL, Hudson J, Cruickshank M, Quinton R, Manson P, et al. Cost‐effectiveness of testosterone treatment utilising individual patient data from randomised controlled trials in men with low testosterone levels. Andrology. 2024. doi:10.1111/andr.13597
BibTeX
@article{Hernndez2024,
author = {Hernández, Rodolfo and de Silva, Nipun Lakshitha and Hudson, Jemma and Cruickshank, Moira and Quinton, Richard and Manson, Paul and Dhillo, Waljit S and Bhattacharya, Siladitya and Brazzelli, Miriam and Jayasena, Channa N},
title = {Cost‐effectiveness of testosterone treatment utilising individual patient data from randomised controlled trials in men with low testosterone levels},
journal = {Andrology},
year = {2024},
doi = {10.1111/andr.13597}
}
EUVIMED